Next Science Ltd (ASX: NXS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Next Science Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Next Science Ltd (ASX: NXS)
Latest News

Share Gainers
Why ANZ, Next Science, Macmahon, and Pointsbet shares are racing higher

Healthcare Shares
Guess which ASX healthcare share is booming 28% on a sales boost

Healthcare Shares
Next Science shares defy ASX market slump to surge 8%

Healthcare Shares
Here's why the Next Science (ASX:NXS) share price is rocketing 11% today

Healthcare Shares
What happened to the Next Science (ASX:NXS) share price last earnings season?

Share Gainers
Next Science (ASX:NXS) share price jumps on record revenue growth

Technology Shares
Next Science (ASX:NXS) share price swings on lowered earnings update

Healthcare Shares
Here's why the Next Science (ASX:NXS) share price finished higher today

Healthcare Shares
Next Science (ASX:NXS) share price falls despite 'exciting future ahead'

Share Gainers
Why Doctor Care Anywhere, Next Science, NIB, & Talga are charging higher

Healthcare Shares
Why the Next Science (ASX:NXS) share price opened 40% higher

Share Fallers
Why Alumina, Delorean, Next Science, & Pushpay shares are tumbling lower
NXS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Next Science Ltd
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.
NXS Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
01 Dec 2023 | $0.24 | $-0.01 | -4.17% | 19,606 | $0.24 | $0.24 | $0.24 |
30 Nov 2023 | $0.24 | $0.01 | 4.26% | 281,649 | $0.24 | $0.24 | $0.23 |
29 Nov 2023 | $0.24 | $0.00 | 0.00% | 173,765 | $0.25 | $0.25 | $0.23 |
28 Nov 2023 | $0.23 | $-0.02 | -8.00% | 372,320 | $0.25 | $0.25 | $0.22 |
27 Nov 2023 | $0.25 | $-0.02 | -7.41% | 625,762 | $0.27 | $0.27 | $0.25 |
24 Nov 2023 | $0.27 | $-0.01 | -3.57% | 119,986 | $0.28 | $0.28 | $0.26 |
23 Nov 2023 | $0.28 | $0.02 | 7.69% | 79,252 | $0.28 | $0.28 | $0.28 |
22 Nov 2023 | $0.26 | $-0.05 | -16.39% | 254,554 | $0.29 | $0.29 | $0.25 |
17 Nov 2023 | $0.31 | $-0.01 | -3.17% | 254,656 | $0.32 | $0.32 | $0.27 |
16 Nov 2023 | $0.32 | $0.01 | 3.23% | 45,459 | $0.32 | $0.32 | $0.31 |
15 Nov 2023 | $0.31 | $0.02 | 6.78% | 122,136 | $0.31 | $0.32 | $0.29 |
14 Nov 2023 | $0.30 | $0.01 | 3.45% | 159,197 | $0.28 | $0.30 | $0.27 |
13 Nov 2023 | $0.29 | $-0.01 | -3.39% | 180,511 | $0.30 | $0.32 | $0.29 |
10 Nov 2023 | $0.30 | $-0.05 | -14.71% | 344,904 | $0.34 | $0.34 | $0.28 |
09 Nov 2023 | $0.34 | $-0.02 | -5.56% | 254,122 | $0.36 | $0.40 | $0.34 |
08 Nov 2023 | $0.36 | $0.06 | 20.00% | 581,573 | $0.31 | $0.39 | $0.31 |
07 Nov 2023 | $0.30 | $0.02 | 7.02% | 241,580 | $0.28 | $0.30 | $0.27 |
06 Nov 2023 | $0.29 | $-0.03 | -9.68% | 357,759 | $0.34 | $0.35 | $0.28 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
01 Nov 2023 | Grant Hummel | Issued | 309,524 | $130,000 |
Placement.
|
01 Nov 2023 | Aileen Stockburger | Issued | 524,801 | $220,416 |
Placement.
|
01 Nov 2023 | Harry Hall(IV) | Issued | 200,000 | $54,440 |
Placement.
|
31 Jul 2023 | Judith Mitchell | Transfer | 420,000 | $220,500 |
Off-market transfer. Assuming off-market transfer of shares
|
31 Jul 2023 | Judith Mitchell | Transfer | 420,000 | $220,500 |
Off-market transfer. Assuming off-market transfer of shares
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Grant Hummel | Non-Executive Director | Aug 2023 |
Mr Hummel has been a partner of a major Australian law firm for over fifteen years. He has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Mr Hummel has been a non-executive director of GLG Corp Ltd since 2018 and serves as the Chair of GLG's Nomination and Remuneration Committee and as a member of GLG's Audit and Risk Committee.
|
Mr Daniel (Dan) Spira | Non-Executive Director | Oct 2017 |
Mr Spira is the CEO of iNova Pharmaceuticals (since 2017) which is a leading multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously he was at Bausch Health (2011-2015) as Vice President and GM-North America (with responsibility for a portfolio of businesses spanning Vision Care, Dermatology and Aesthetic Devices) and was also Managing Director, Pacific region. Prior to that, Mr Spira spent over 15 years at Johnson & Johnson Inc in various roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions.
|
Ms Aileen Stockburger | Non-Executive DirectorNon-Executive Chairman | Oct 2018 |
Prior to joining Next Science, Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms.
|
Ms Katherine (Kathy) Ostin | Non-Executive Director | Oct 2023 |
Ms Ostin is a non-executive director and audit and risk committee chair. Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017. During her 24 years with KPMG, Ms Ostin worked in Australia, the US, Asia, and the UK. Ms Ostin currently serves as a Non-Executive Director of 3P Learning Limited (ASX:3PL), dusk Group Limited (ASX:DSK), Capral Limited (ASX:CAA) and Alex Corporation Limited.
|
Mr Harry Thomas Hall(IV) | Chief Executive OfficerManaging Director | Jul 2023 |
Mr Hall has 28 years in the global medical device industry, I.V. has held general management roles including product development, global strategic marketing, commercial operations, and sales leadership. I.V. joined DePuy Synthes, a subsidiary of Johnson and Johnson (NYSE: JNJ) in 1997 where he held senior roles including: Global Vice President - MedTech R&D and Worldwide President Trauma, Extremities, Craniomaxillofacial & Animal Health. I.V. was most recently a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes and completed the launch of the first surgical robot developed by JNJ / DePuy Synthes. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, I.V.
|
Ms Gillian Maria Nairn | Company Secretary | Jun 2018 |
-
|
Jacqueline Butler | Chief Financial Officer |
-
|
|
Matthew Myntti | Chief Technology Officer |
-
|
|
Gillian Maria Nairn | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Auckland Trust Company Ltd | 56,019,938 | 26.08% |
Walker Group Holdings Pty Limited | 26,877,123 | 12.51% |
Hsbc Custody Nominees (Australia) Limited A/C 2 | 11,563,164 | 5.38% |
Dr Matthew Franco Myntti | 10,472,969 | 4.88% |
Ubs Nominees Pty Ltd | 6,959,201 | 3.24% |
Hsbc Custody Nominees (Australia) Limited | 5,338,314 | 2.49% |
Judith Lee Mitchell | 5,129,936 | 2.39% |
Mr Charles Robert Dirck Wittenoom | 3,000,000 | 1.40% |
Sandhurst Trustees Ltd <Endeavor Asset Mgmt Mda A/C> | 2,845,857 | 1.32% |
J P Morgan Nominees Australia Pty Limited | 2,789,351 | 1.30% |
Citicorp Nominees Pty Limited | 2,634,289 | 1.23% |
National Nominees Limited | 2,474,702 | 1.15% |
Bnp Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 1,973,603 | 0.92% |
Bond Street Custodians Limited <Lam1 D08047 A/C> | 1,460,427 | 0.68% |
Mr James Fong Seeto | 1,400,000 | 0.65% |
Brook St Smsf Pty Ltd <Brook St Smsf A/C> | 1,255,702 | 0.58% |
G & N Lord Superannuation Pty Ltd <Gnr Superannuation Fund A/C> | 965,000 | 0.45% |
Twenty Fifth Elporto Pty Limited <Twenty Fifth Elporto Sf A/C> | 900,000 | 0.42% |
Ka-Tet Pty Ltd <The Rosenrot Trust> | 890,500 | 0.41% |
Mrs Desiree Hancox Darroch | 815,500 | 0.38% |